Lake Mary, Fla. (October 4, 2010) – Axium Healthcare Pharmacy , one of the nation’s largest independent specialty pharmacy providers, has been granted access to provide ELAPRASE for the treatment of pediatric patients with Hunter syndrome.
ELAPRASE is an orphan drug, designed to treat the underlying cause of Hunter syndrome by replacing the deficient or absent iduronate-2sulfatase (I2S) enzyme. ELAPRASE is an infused medication generally administered in the hospital setting. Axium will play a key role in working with the insurance companies to obtain prior authorization and reauthorization for ELAPRASE. ELAPRASE is manufactured by Shire Human Genetic Therapies, Inc.
“Axium is pleased to be granted the opportunity to be a provider of ELAPRASE in Puerto Rico,” stated Mark Montgomery, President & CEO of Axium Healthcare Pharmacy. “This selection continues to build momentum on Axium’s strong clinical programs and our investment in providing solutions for our clients.”
Axium’s clinical team provides comprehensive compliance support, patient education and other clinical interventions and communication with the patient/physician to coordinate the treatment plan. In addition, Axium offers 24-hour Pharmacist/ Nurse support, prior authorization assistance, refill management calls, and ongoing delivery coordination.
About Axium Healthcare Pharmacy:
Axium’s clinical team provides comprehensive compliance support, patient education and other clinical interventions and communication with the patient/physician to coordinate the treatment plan. In addition, Axium offers 24-hour Pharmacist/ Nurse support, prior authorization assistance, refill management calls, and ongoing delivery coordination. For more information, contact Axium Healthcare Pharmacy at 888.315.3395; by email [email protected]
Press Release Distribution by VayuMedia
